SOBI Share Price Performance
SEK 0
-287.80 (-100.00%)
Price SEK 0
Fair ValueSEK 423.60
Share Pricen/a
Swedish Orphan Biovitrum AB (publ) Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
SOBI Community Narratives
AN
Fair Value SEK 423.6 10.2% undervalued intrinsic discount
SOBI: Upgraded Recommendation Signals Confidence Amid Balanced Risks And Advancing Pipeline
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
Fair Value SEK 450 15.4% undervalued intrinsic discount
Launch Wave In Rare Disease Treatments Will Redefine Long Term Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value SEK 315 20.8% overvalued intrinsic discount
Pipeline And Margin Risks Will Challenge Rare Disease Expansion Narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
SOBI: Upgraded Recommendation Signals Confidence Amid Balanced Risks And Advancing Pipeline
Key Takeaways Successful Altuvoct launch in Europe and expanding regulatory approvals for Aspaveli and Gamifant could significantly boost revenue through market share growth and new entries. Strategic operational efficiency, cost management, and increased Beyfortus royalties are expected to enhance margins and stabilize earnings.Read more
184
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
SEK 423.6
10.2% undervalued intrinsic discount
Fair Value
Revenue
11.87% p.a.
Profit Margin
22.04%
Future PE
20.07x
Price in 2029
SEK 496.43
Pipeline And Margin Risks Will Challenge Rare Disease Expansion Narrative
Catalysts About Swedish Orphan Biovitrum Swedish Orphan Biovitrum focuses on rare disease medicines across hematology, immunology and specialty care. What are the underlying business or industry changes driving this perspective?Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 315
20.8% overvalued intrinsic discount
Fair Value
Revenue
8.96% p.a.
Profit Margin
16.92%
Future PE
21.05x
Price in 2029
SEK 369.09
Launch Wave In Rare Disease Treatments Will Redefine Long Term Potential
Catalysts About Swedish Orphan Biovitrum Swedish Orphan Biovitrum focuses on rare diseases in hematology, immunology and specialty care, with a growing portfolio of high-value medicines. What are the underlying business or industry changes driving this perspective?Read more
15
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 450
15.4% undervalued intrinsic discount
Fair Value
Revenue
14.45% p.a.
Profit Margin
24.94%
Future PE
17.61x
Price in 2029
SEK 527.53
Trending Discussion
Recently Updated Narratives
AN
SOBI: Kidney And Sepsis Progress Will Support A More Constructive Outlook
Fair Value: SEK 423.6 10.2% undervalued intrinsic discount
10 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Pipeline And Margin Risks Will Challenge Rare Disease Expansion Narrative
Fair Value: SEK 315 20.8% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Launch Wave In Rare Disease Treatments Will Redefine Long Term Potential
Fair Value: SEK 450 15.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Swedish Orphan Biovitrum AB (publ) Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Mar 31, 2026
- 1.38
- 78.87%
- 1.69%
- 29.5%
About SOBI
- Founded
- 1939
- Employees
- 1888
- CEO
- WebsiteView website
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Aloxi, Jyseleca, Kepivance, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Stockholm, Sweden.
